HBMHF (HBM Holdings) Research & Development: $39.8 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HBMHF HBM Holdings Ltd HBMHF
73 GF Score
Price $1.56
GF Value $0.87
! 4 Warning Signs
View Full Analysis

What is HBM Holdings Research & Development?

HBM Holdings HBMHF 73 Research & Development is $39.8 Mil as of Dec. 2025. GuruFocus rates HBMHF with a GF Score™ of 73/100 and a GF Value™ of $0.87. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. HBM Holdings's Research & Development for the six months ended in Dec. 2025 was $21.8 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $39.8 Mil.

HBM Holdings  (OTCPK:HBMHF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

HBM Holdings Research & Development Related Terms

HBM Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for HBM Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HBM Holdings Research & Development Chart

HBM Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 107.10 135.14 45.08 21.00 39.77

HBM Holdings Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.70 13.10 7.90 17.96 21.81
HBMHF
73GF Score
HBM Holdings Ltd HBMHF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HBM Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $39.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $39.8 Mil mean?
HBM Holdings (HBMHF) has a Research & Development of $39.8 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on HBM Holdings and its competitors.
Is HBM Holdings' Research & Development too high?
HBM Holdings' current Research & Development is $39.8 Mil. Overall, HBM Holdings has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' Research & Development compare to VRTX and REGN?
HBM Holdings' Research & Development of $39.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on HBM Holdings and its competitors. HBM Holdings's current Research & Development is $39.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
HBM Holdings (HBMHF) has a current Research & Development of $39.8 Mil. The stock's GF Value™ is $0.87, compared to a current price of $1.56 — trading 79.3% above its estimated fair value. The current Research & Development is $39.8 Mil. HBM Holdings' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For HBM Holdings (HBMHF), the current Research & Development is $39.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HBM Holdings (HBMHF) Overvalued in 2026?

Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued. The current stock price of $1.56 is trading 79.3% above its estimated GF Value™ of $0.87.

Key valuation signals for HBMHF:

  • Research & Development: $39.8 Mil
  • GF Value™: $0.87 vs. price of $1.56 (79.3% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the HBMHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HBM Holdings Business Description

Other Exchanges 02142:Hong Kong6XY:Germany
Address No. 388 Fenglin Road, 6th Floor, Tower B, Fenglin International Phase I, Xuhui District, Shanghai, CHN, 200032
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
73GF Score

Get the complete analysis for HBMHF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.56
Price
$0.87
GF Value